241 related articles for article (PubMed ID: 18318431)
1. Establishing treatment benchmarks for mammography-screened breast cancer population based on a review of evidence-based clinical guidelines.
Delaney G; Shafiq J; Chappell G; Barton M
Cancer; 2008 May; 112(9):1912-22. PubMed ID: 18318431
[TBL] [Abstract][Full Text] [Related]
2. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines.
Delaney G; Jacob S; Featherstone C; Barton M
Cancer; 2005 Sep; 104(6):1129-37. PubMed ID: 16080176
[TBL] [Abstract][Full Text] [Related]
3. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part II--carcinoma of the endometrium.
Delaney G; Jacob S; Barton M
Cancer; 2004 Aug; 101(4):682-92. PubMed ID: 15305397
[TBL] [Abstract][Full Text] [Related]
4. Estimating the optimal radiotherapy utilization for carcinoma of the central nervous system, thyroid carcinoma, and carcinoma of unknown primary origin from evidence-based clinical guidelines.
Delaney G; Jacob S; Barton M
Cancer; 2006 Jan; 106(2):453-65. PubMed ID: 16355366
[TBL] [Abstract][Full Text] [Related]
5. Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma: a review of the evidence.
Delaney G; Barton M; Jacob S
Cancer; 2004 Aug; 101(4):657-70. PubMed ID: 15305395
[TBL] [Abstract][Full Text] [Related]
6. Estimation of an optimal external beam radiotherapy utilization rate for head and neck carcinoma.
Delaney G; Jacob S; Barton M
Cancer; 2005 Jun; 103(11):2216-27. PubMed ID: 15856428
[TBL] [Abstract][Full Text] [Related]
7. Estimation of an optimal radiotherapy utilization rate for breast carcinoma: a review of the evidence.
Delaney G; Barton M; Jacob S
Cancer; 2003 Nov; 98(9):1977-86. PubMed ID: 14584082
[TBL] [Abstract][Full Text] [Related]
8. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part I--malignancies of the cervix, ovary, vagina and vulva.
Delaney G; Jacob S; Barton M
Cancer; 2004 Aug; 101(4):671-81. PubMed ID: 15305396
[TBL] [Abstract][Full Text] [Related]
9. Estimation of an optimal chemotherapy utilisation rate for breast cancer: setting an evidence-based benchmark for the best-quality cancer care.
Ng W; Delaney GP; Jacob S; Barton MB
Eur J Cancer; 2010 Mar; 46(4):703-12. PubMed ID: 20034784
[TBL] [Abstract][Full Text] [Related]
10. Estimating the optimal external-beam radiotherapy utilization rate for genitourinary malignancies.
Delaney G; Jacob S; Barton M
Cancer; 2005 Feb; 103(3):462-73. PubMed ID: 15612081
[TBL] [Abstract][Full Text] [Related]
11. Estimation of an optimal radiotherapy utilization rate for melanoma: a review of the evidence.
Delaney G; Barton M; Jacob S
Cancer; 2004 Mar; 100(6):1293-301. PubMed ID: 15022299
[TBL] [Abstract][Full Text] [Related]
12. Estimation of an optimal chemotherapy utilisation rate for colon cancer: an evidence-based benchmark for cancer care.
Jacob S; Ng W; Asghari R; Delaney GP; Barton MB
Eur J Cancer; 2009 Sep; 45(14):2503-9. PubMed ID: 19527926
[TBL] [Abstract][Full Text] [Related]
13. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-leukemia and myeloma.
Featherstone C; Delaney G; Jacob S; Barton M
Cancer; 2005 Jan; 103(2):393-401. PubMed ID: 15593373
[TBL] [Abstract][Full Text] [Related]
14. Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care.
Ng W; Jacob S; Delaney G; Barton M
Eur J Cancer; 2009 Aug; 45(12):2150-9. PubMed ID: 19285857
[TBL] [Abstract][Full Text] [Related]
15. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part I-lymphoma.
Featherstone C; Delaney G; Jacob S; Barton M
Cancer; 2005 Jan; 103(2):383-92. PubMed ID: 15599937
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy in rectal cancer: variation in utilization and development of an evidence-based benchmark rate of optimal chemotherapy utilization.
Jacob S; Ng W; Asghari R; Delaney GP; Barton MB
Clin Colorectal Cancer; 2011 Jun; 10(2):102-7. PubMed ID: 21859561
[TBL] [Abstract][Full Text] [Related]
17. Estimation of an evidence-based benchmark for the optimal endocrine therapy utilization rate in breast cancer.
Fong A; Ng W; Barton MB; Delaney GP
Breast; 2010 Oct; 19(5):345-9. PubMed ID: 20223666
[TBL] [Abstract][Full Text] [Related]
18. Is mode of breast cancer detection associated with cancer treatment in the United States?
Yabroff KR; Harlan LC; Clegg LX; Ballard-Barbash R; Stevens J; Weaver DL
Cancer; 2008 Mar; 112(5):1011-9. PubMed ID: 18189297
[TBL] [Abstract][Full Text] [Related]
19. Defining the need for breast cancer radiotherapy in the general population: a criterion-based benchmarking approach.
Kerba M; Miao Q; Zhang-Salomons J; Mackillop W
Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):481-9. PubMed ID: 17467249
[TBL] [Abstract][Full Text] [Related]
20. A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy.
Fong A; Shafiq J; Saunders C; Thompson AM; Tyldesley S; Olivotto IA; Barton MB; Dewar JA; Jacob S; Ng W; Speers C; Delaney GP
Breast; 2012 Aug; 21(4):570-7. PubMed ID: 22425535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
